Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

EGEngin GulSSSmriti SharmaJSJiandong Su

Discussion

Loading...

Member takes

Overview

Retrospective study shows DRd improves progression-free survival as standard of care for transplant-ineligible patients.

Key Points

  • This study evaluates the real-world outcomes of first-line regimens in transplant-ineligible patients with multiple myeloma.
  • Retrospective observational analysis using the Canadian Myeloma Research Group Database.
  • Included transplant-ineligible patients treated with CyBorD, Rd, RVd, or DRd from 2018 to 2024.
  • Excluded patients on clinical trials or with specific diagnoses like amyloidosis.
  • 1,085 patients were eligible, with DRd becoming the most common first-line regimen.
  • Overall response rates were high, with DRd showing improved progression-free survival compared to CyBorD.
  • Early mortality rates were low across all regimens, especially with DRd.

Cite This Study

Gul et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da78https://doi.org/10.1182/blood-2025-2798
View Full Paper
Ask AI
Bookmark
Share